Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for immunotherapy

A composition and immunotherapy technology, applied in biochemical equipment and methods, chemical equipment and methods, drug combinations, etc., can solve problems such as off-target toxicity

Pending Publication Date: 2020-03-24
OBSIDIAN THERAPEUTICS INC
View PDF196 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Furthermore, administration of engineered T cells can lead to on-target / off-target toxicity as well as cytokine release syndrome (reviewed by TeyClin.Transl.Immunol., 2014, 3:e17 10.1038)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for immunotherapy
  • Compositions and methods for immunotherapy
  • Compositions and methods for immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0245] The preparation of antibodies, whether monoclonal antibodies or polyclonal antibodies, is known in the art. Techniques for producing antibodies are well known in the art and are described in, for example, Harlow and Lane "Antibodies, A Laboratory Manual", Cold Spring Harbor Laboratory Press, 1988; Harlow and Lane "Using Antibodies: A Laboratory Manual" Cold Spring Harbor Laboratory Press , 1999 and "Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry" Woodhead Publishing, 2012.

[0246] Recombinant polynucleotides can be used to produce antibodies and fragments and variants thereof as described herein. In one embodiment, the polynucleotide has a modular design that encodes at least one of an antibody, fragment or variant thereof. As a non-limiting example, the polynucleotide construct can encode any of the following designs: (1) antibody heavy chain; (2) antibody light chain; (3) antibody heavy and...

Embodiment 1

[0672] Example 1. Generation of novel ligand-responsive SRE or DD through mutagenesis screening

[0673] Research design

[0674] In order to engineer a construct that exhibits ligand-dependent stability, a candidate ligand binding domain (LBD) was selected, and a cell-based screen using yellow fluorescent protein (YFP) as a reporter of protein stability was designed to Identification of candidate LBD mutants with the desired characteristics of the destabilizing domain: low protein levels (ie, low basic stability) in the absence of LBD ligands, large dynamic range, robust dose-response behavior, and reliable The prediction and degradation kinetics are fast (Banaszynski et al., (2006) Cell; 126(5):995-1004). The candidate LBD binds the desired ligand, but not the endogenous signaling molecule.

[0675] First, a combination of nucleic acid analogue right and error-prone PCR is used to mutate the candidate LBD sequence (as a template) to generate a mutant library based on the templat...

Embodiment 2

[0683] Example 2. DD regulates the expression of recombinant IL2

[0684] FKBP (L106P) and ecDHFR (R12Y, Y100I) are well-characterized destabilizing domains that can impart instability to fusion partners (eg, POI). This instability is reversed by a synthetic ligand called Shield-1 that binds to FKBP DD and a synthetic ligand called TMP or MTX that binds to DHFR DD. Link the IL2 polypeptide to FKBP (F36V; L106P) or ecDHFR (R12Y, Y100I). The IL2 construct was packaged into the pLVX-IRES-Puro lentiviral vector. The IL2 signal sequence was inserted at the N-terminus of the construct, and the linker was placed between the signal sequence DD and IL2.

[0685] OT-IL2-001 (FKBP) was transduced into the human colorectal cancer strain HCT-116. To measure the dependence of IL2 levels on the dose of Shield-1, cells were plated on 96-well plates and treated with different concentrations of Shield-1. The culture medium was then collected from the cells and IL2 ELISA was used to quantify IL2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.

Description

[0001] Cross references to related applications [0002] This application requires submission of U.S. Provisional Patent Application No. 62 / 466,601 on March 3, 2017 named Compositions and Methods for Immunotherapy, and U.S. Provisional Patent Application No. 62 / filed on April 11, 2017 named Compositions and Methods for Immunotherapy. 484,063 and the priority of U.S. Provisional Patent Application 62 / 542,402 filed on August 8, 2017 under the name Compositions and Methods for Immunotherapy, the content of each patent is incorporated herein by reference in its entirety. [0003] Sequence Listing [0004] This application is submitted together with the sequence table in electronic format. The sequence listing is provided as a file named 2095_1207PCT_SL.txt created on March 2, 2018, and the size of the file is 1,566,189 bytes. The information in the sequence listing in electronic format is incorporated herein by reference in its entirety. Technical field [0005] The present invention r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P37/02C07K14/54C07K14/55A61K39/39
CPCA61K39/39C07K14/54C07K14/55C07K14/705C07K14/47C07K14/4702C12Y304/14005C12Y402/01001C12Y502/01008C12N9/003C12N9/0055C12N9/16C12N9/485C12Y105/01003C12N9/6472C12N9/88C12N9/90C12N15/62C07K2319/00C07K2319/01C12Y301/04053A61P37/02A61K2039/55533C12N2710/16234A61K2039/585A61P35/00A61K2039/82C07K2319/03C07K14/7051Y02A50/30A61K39/464417A61K39/464406A61K39/464402A61K39/4611A61K39/464463A61K2239/29A61K39/464412A61K39/464471A61K2239/31A61K39/4631
Inventor V·苏瑞K·G·埃尔佩克M·L·奥尔斯B·多林斯基N·科米德S·F·海勒A·库尔卡尼M·C·英尼斯D·J·李
Owner OBSIDIAN THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com